ArticleInternational journal of fertility & sterility2025
Extracellular Vesicles Present in Bone Marrow Mesenchymal Stromal/Stem Cell Conditioned Media Restore Spermatogenesis in Azoospermic Mice.
Article in International journal of fertility & sterility, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to examine the therapeutic efficacy of exosome-enriched conditioned media (CM), known for its high concentration of extracellular vesicles (EVs), in comparision with mesenchymal stromal/stem cells (MSCs) in treating non-obstructive azoospermia. MATERIALS AND
methodsIn this experimental study, we used adipose tissue-derived MSCs (AT-MSCs), bone marrowderived MSCs (BM-MSCs), and BMCM containing EVs to treat busulfan-induced azoospermia in animal models. The study included thirty adult male Balb/C mice and two female enhanced green fluorescent protein-positive (eGFP+/+) Balb/C mice for experimental groups and stem cell culturing. Groups consisted of an intact control, an azoospermia group, an AT-MSC therapy group, a BM-MSC therapy group, a BMCM therapy group, and a spontaneous healing group. Testes were removed from all mice, and histomorphometry and flow cytometry analyses were performed 60 days post-treatment. Additionally, protein structure extraction, protein-protein docking analysis, and data visualization were conducted.
resultsHistomorphometry and flow cytometry showed that most seminiferous tubules in the therapy groups exhibited normal morphology and restored spermatogenesis, unlike the azoospermia group. In silico protein docking analysis revealed that exosome factors in BM-MSCs positively impacted spermatogenesis. The BM-MSC and BMCM therapy groups showed more favorable outcomes compared to other groups. Key exosome factors like Basigin, E3 ubiquitinprotein ligase (UBR2), transforming growth factor beta (TGF-β), hepatocyte growth factor (HGF), and programmed death-ligand 1 (PD-L1) interacted with receptors critical to this process.
conclusionOur findings indicate that both BMCM enriched with EVs and the administration of AT-MSCs and BM-MSCs effectively induced spermatogenesis in mice with busulfan-induced azoospermia. Specifically, BM-MSC therapy exhibited superior outcomes compared to AT-MSCs and BMCM alone. This study highlights the potential of EV-based therapies, particularly BMCM, as a promising strategy for treating non-obstructive azoospermia. Furthermore, the interaction of key exosome factors with critical receptors enhances our understanding of the underlying molecular mechanisms involved in restoring reproductive function in testes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.